This bill removes the legal provision that set a termination date for the Louisiana Behavior Analyst Board, allowing the regulatory body to continue operating. By repealing the specific statute that established the board's expiration, the legislation ensures the board remains active for overseeing behavior analysts in the state. The change directly affects the board's ability to regulate professionals and maintain oversight without a fixed end date. No new powers or requirements are added; the bill simply eliminates the existing deadline for the board's existence.
This bill requires health insurance companies in Louisiana to cover mobile crisis response and behavioral health crisis care services when provided by eligible licensed providers. The law mandates that these services do not need prior authorization from insurers and allows providers to coordinate with the state's Crisis Hub for information sharing. Coverage may include standard cost-sharing options like deductibles and copayments, while reimbursement methods remain up to each insurer's discretion. The bill defines these services as short-term, recovery-focused interventions for adults and children experiencing mental health or substance use crises, with an effective date of July 1, 2027.
HB 591 proposes creating a new "Paid Family Leave Insurance Act" in Louisiana, allowing insurers to offer voluntary wage replacement coverage for employees taking time off for specific family reasons. The bill would enable employers or employees to purchase insurance policies covering up to 12 weeks of paid leave annually for qualifying events like a new child’s birth/adoption, caring for a family member with a serious health condition, or addressing military-related exigencies. Key provisions require policies to specify minimum benefit amounts (at least two weeks of coverage within 52 weeks), define eligibility, and detail how benefits are calculated based on wages. This legislation, currently pending in the Louisiana legislature, would establish a state-regulated insurance framework but does not mandate employer coverage or create a state-run program.
HB 807 establishes a special fund within Louisiana's state treasury to support the Community and Technical College System's workforce training programs. It directly affects community colleges and private-sector employers in high-demand industries like healthcare, manufacturing, and information technology by providing funding to hire more instructors and expand training capacity. Key provisions include using the fund for rapid-response instructor deployment, recruitment incentives, temporary instructors, and salary supplements - while prohibiting these funds from replacing existing state higher education funding. The program requires annual reporting to legislative committees on fund usage, supported industries, and credentials awarded.
HB 761 creates an advisory board within Louisiana's Department of Health to review and recommend new treatments for rare cancers. The 17-member board includes health officials, cancer researchers, oncologists from major institutions (like LSU, Tulane, and Xavier), and representatives from cancer research centers. The board must hold quarterly public meetings, compile findings within 30-45 days, and submit written reports to the Insurance Committees of both legislative chambers. This process directly affects how the Department of Health evaluates rare cancer treatments, streamlining recommendations to the agency for potential adoption.
HB 895 requires Louisiana hospitals and healthcare providers to offer sexual assault survivors specific medical treatments without undue delay. It mandates that providers make emergency contraception available and provide at least a three-day supply of HIV/STI prevention medication when medically needed, alongside private examinations adapted to each survivor's needs. The bill also requires hospitals to offer a survivor advocate (with confidential communications) during forensic exams, with the survivor's consent. This directly affects sexual assault survivors receiving emergency medical care in Louisiana hospitals.
HB 291 prevents health insurers in Louisiana from penalizing hospitals or clinics (participating healthcare facilities) solely because another provider at that facility - like a doctor or specialist - is dropped from the insurer's network. The bill directly affects healthcare facilities that coordinate patient care with multiple providers, ensuring they won’t face payment cuts or contract terminations due to a partner provider’s network status. Key provisions ban insurers from reducing payments or ending agreements with facilities based on another provider’s network exclusion, and require that any contract clauses attempting to override this rule are void. This policy change aims to stabilize provider relationships and care continuity for patients.
HB 823 establishes a pilot program in Orleans Parish that offers homeless individuals facing criminal charges an alternative to court proceedings. Instead of traditional sentencing, eligible defendants can participate in a diversion program providing housing assistance, mental health services, job training, and substance abuse treatment. If participants successfully complete the program’s requirements, the criminal charges are dismissed without a conviction. The program requires annual evaluations and reporting to the Louisiana Supreme Court, aiming to reduce recidivism, court workload, and prison overcrowding while addressing homelessness through community partnerships.
HB 766 requires health insurers in Louisiana to cover orally administered anti-cancer medications on the same terms as intravenously administered ones. It prohibits insurers from imposing higher copays, deductibles, or prior authorizations for oral medications compared to IV treatments, and bans programs that ignore drug discounts (like "accumulator" programs). The bill caps out-of-pocket costs for oral anti-cancer drugs at $100 per prescription and ensures cost-sharing counts toward annual out-of-pocket maximums. It applies to most health plans but excludes limited-benefit policies, high-deductible plans with HSAs, and self-funded ERISA plans. This directly affects cancer patients and insurers by reducing financial barriers to oral medication access.
HCR 120 establishes the PACE Task Force to study GLP-1 medications, which are drugs used for diabetes and weight loss that have seen a massive increase in demand and cost in Louisiana. This concurrent resolution directs the task force to investigate how these drugs affect insurance premiums, accessibility for different income groups, and the long-term financial impact on both public and private insurers. The group will consist of representatives from state agencies, health plans, and medical providers, who will meet to analyze pricing differences between diabetes and weight loss uses before submitting their findings to the legislature by February 2027.